Taysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Here's What Happened

Key Points

• Taysha Gene Therapies (TSHA) hit a new 52-week high intraday of $6.81, last trading around $6.63 on roughly 255,000 shares and a market capitalization near $1.92 billion.
• Analysts have been upgrading the stock — including Truist's "strong-buy" and Needham lifting its target to $12 — leaving a consensus rating of Buy and a consensus price target of $11.64.
• The company reported quarterly results that beat expectations (EPS -$0.08 vs. -$0.11 expected; revenue $5.49M vs. $1.89M expected) and remains a clinical-stage gene-therapy developer focused on rare CNS monogenic diseases with lead programs TSHA-101/102/103.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $6.81 and last traded at $6.6250, with a volume of 254924 shares traded. The stock had previously closed at $6.64.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Truist Financial upgraded shares of Taysha Gene Therapies to a "strong-buy" rating in a research report on Wednesday, March 25th. Wall Street Zen upgraded shares of Taysha Gene Therapies from a "sell" rating to a "hold" rating in a research report on Saturday, March 21st. Needham & Company LLC raised their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, March 19th. Wells Fargo & Company raised their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, January 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $11.64.

Taysha Gene Therapies Stock Performance

The firm's 50 day moving average is $4.95 and its two-hundred day moving average is $4.89. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23. The stock has a market capitalization of $1.92 billion, a PE ratio of -19.61 and a beta of 1.25.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million during the quarter, compared to analysts' expectations of $1.89 million. As a group, research analysts predict that Taysha Gene Therapies, Inc. will post -0.41 earnings per share for the current year.

Insider Transactions at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the business's stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the sale, the insider owned 1,136,410 shares of the company's stock, valued at $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by company insiders.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Marex Group plc acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at approximately $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at about $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies during the 3rd quarter valued at about $40,000. Tower Research Capital LLC TRC boosted its stake in Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock valued at $41,000 after purchasing an additional 10,742 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Taysha Gene Therapies by 143.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock valued at $43,000 after purchasing an additional 4,607 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.